Back to EveryPatent.com
United States Patent | 5,510,328 |
Polarek ,   et al. | April 23, 1996 |
The present invention provides methods for reducing or inhibiting wound contraction in a subject having a wound comprising administering to the subject a pharmaceutical composition comprising a peptide or a polypeptide. The invention provides, for example, a method of reducing or inhibiting wound contraction comprising the administration of a pharmaceutical composition comprising a peptide having more than three consecutive basic amino acids. The invention also provides a method of reducing or inhibiting wound contraction comprising the administration of a pharmaceutical composition comprising decorin.
Inventors: | Polarek; James (Del Mar, CA); Tamura; Richard (San Diego, CA); Harper; John (Carlsbad, CA) |
Assignee: | La Jolla Cancer Research Foundation (La Jolla, CA) |
Appl. No.: | 234979 |
Filed: | April 28, 1994 |
Current U.S. Class: | 514/8; 514/14; 514/16; 514/17; 530/326 |
Intern'l Class: | A61K 038/16; C07K 007/08 |
Field of Search: | 514/8,14,16,17 530/326 |
4517686 | May., 1985 | Ruoslahti et al. | 3/1. |
4578079 | Mar., 1986 | Ruoslahti et al. | 623/11. |
4589881 | May., 1986 | Pierschbacher et al. | 623/11. |
4614517 | Sep., 1986 | Ruoslahti et al. | 623/11. |
4661111 | Apr., 1987 | Ruoslahti et al. | 623/11. |
4792525 | Dec., 1988 | Ruoslahti et al. | 435/240. |
5041380 | Aug., 1991 | Rouslahti et al. | 435/240. |
Foreign Patent Documents | |||
WO9006767 | Jun., 1990 | WO. |
Schreiber, Ronda E. "Reversal of RGD Peptide-Mediated Wound Contraction Enhancement by Incorporation of a Poly-Cationic Sequence." Wounds 6:72 (1994). Harper, John "The Role of TGF-.beta. and Decorin in Controlling Fibrosis." Wounds 6:70 (1994). Kresse, H. et al., "Biosynthesis and Interactions of Small Chondrotin/Dermatan Sulphate Proteoglycans." Eur. J. Clin. Chem. Clin. Biochem. 32:259-264 (1994). Brown, David C. and Vogel, Kathryn G. "Characteristics of the In Vitro Interaction of a Small Proteoglycan (PG11) of Bovine Tendon with Type 1 Collagen." Matrix 9:468-478 (1989). Vogel, Kathryn G. et al., "Specific Inhibition of Type I and Type II Collagen Fibrillogenesis by the Small Proteoglycan of Tendon." Biochem. J. 223:587-597 (1984). Greve, Herman et al., "Influence of Collagen Lattice on the Metabolism of Small Proteoglycan II by Cultured Fibroblasts." Biochem. J. 269:149-155 (1990). Ruoslahti, Erkki, "Structure and Biology of Proteoglycans." Ann. Rev. Cell. Biol. 4:229-255 (1988). Vogel, Kathryn G. and Trotter, John A. "The Effect of Proteoglycans on the Morphology of Collagen Fibrils Formed in Vitro." Collagen Rel. Res. 7:105-114 (1987). Polarek, James W. et al., "Development of a Provisional Extracellular Matrix to Promote Wound Healing." Wounds 6:46-53 (1994). Guidry, Clyde and Grinnell, Frederick "Heparin Modulates the organization of Hydrated Collagen Gels and Inhibits Gel Contraction by Fibroblasts." J. Cell Biol. 104:1097-1103 (1987). Agrez, M. V. and Chua, F. K. "The Role of Colon Fibroblasts in Malignant Large Bowel Obstruction-an Experimental in Vitro Model." Br. J. Cancer. 62:567-572 (1990). Gullberg, Donald, et al., ".beta..sub.1 Integrin-Mediated Collagen Gel Contraction is Stimulated by PDGF." Experimental Cell Res. 186:264-272 (1990). Guidry, Clyde and Grinnell, Frederick "Studies on the Mechanism of Hydrated Collagen Gel Reorganization by Human Skin Fibroblasts." J. Cell Sci. 79:67-81 (1985). Staatz, William D. et al., "The .alpha..sub.2 .beta..sub.1 Integrin Cell Surface Collagen Receptor Binds to the .alpha.1(I)-CB3 Peptide of Collagen." J. Biol. Chem. 265:4778-4781 (1990). Donaldson, Donald J. and Mahan, James T. "Newt Epidermal Cell Migration In Vitro and In Vivo Appears to Involve Arg-Gly-Asp-Ser Receptors." J. Cell Science. 87:525-534 (1987). Smith, Daniel J. et al., "Video Image Analysis of Wound Repair." Wounds 4:6-15 (1992). Burgess, Maria Lonnett et al., "Integrin-Mediated Collagen Gel Contraction by Cardiac Fibroblasts." Circulation Res. 74:291-298 (1994). Debhar, Shoukat et al., "A Cell Surface Receptor Complex for Collagen Type Recognizes the Arg-Gly-Asp Sequence." J. Cell Biol. 104: 585-593 (1987). Agrez, Michael V. et al., "Arg-Gly-Asp-Containing Peptides Expose Novel Collagen Receptors on the Fibroblasts: Implications for Wound Healing." Cell Regulation 2:1035-1044 (1991). Tomasek, James J. and Akiyama, Steven K. "Fibroblast-Mediated Collagen Gel Contraction Does Not Require Fibronectin-.alpha..sub.5 .beta..sub.1 Integrin Interaction." Anatomical Record 234:153-160 (1992). Cardarelli, Pina M. et al., "The Collagen Receptor .alpha.2.beta.1, from MG-63 and HT1080 Cells, Interacts with a Cyclic RGD Peptide" J. Biol. Chem. 267:23159-23164 (1992). Albina, Jorge E. et al., "Regulation of Macrophage Functions by 1-Arginine." J. Exp. Med. 169:1021-1029 (1989). Albina, Jorge E. et al., "Arginine Metabolism in Wounds." Am. J. Physiol. 254:E459-E467 (1988). Albina, Jorge E. et al., "Temporal Expression of Different Pathways of 1-Agrinine Metabolism in Healing Wounds." J. Immun. 144:3877-3880 (1990). Barbul, Adrian et. al., "Intravenous Hyperalimentation with High Arginine Levels Improves Wound Healing and Immune Function." J. Surgical Res. 38:328-334 (1985). Mills, Charles D. et al., "Concomitant Macrophage Activation and Fibroblast/Lymphocyte Inhibition by Wound Fluid: The Arginine-Deficiency of Inflammation is" a Partial Explanation. Clinical and Experimental Approaches to Dermal and Epiderman Repair: Normal and Chronic Wounds, p:193-203 Wiley-Liss, Inc. (1991). Grinnell, Frederick et al., "The Collagen Recognition Sequence for Fibroblasts Depends on Collagen Topography." Experimental Cell Res. 182:668-672 (1989). Grinnell, Frederick "Mini-Review on the Cellular Mechanisms of Disease: Fibroblasts, Myofibroblasts and Wound Contraction." J. Cell Biol. 124:401-404 (1994). |
TABLE 1 ______________________________________ PEPTIDES NAME Amino Acid Sequence* ______________________________________ WH18 G--{(D)R}.sub.5 --GGG--(D)R--GDSPASSK WH18ILE G--{(D)R}.sub.5 --GGG--(D)R--GDIPASSK WH18RAD G--{(D)R}.sub.5 --GGG--(D)R--ADSPASSK 15P YGRRRRRQRRRP (SEQ ID NO: 1) 23N GAARGDTPE--NH.sub.2 (SEQ ID NO: 2) ______________________________________ *Amino acid residues are indicated by their single letter code. (D)R indicates the Damino acid form of arginine. Bold print indicates the amino acid residues involved in the lactam bond; 23N is a cyclic peptide.
__________________________________________________________________________ SEQUENCE LISTING (1) GENERAL INFORMATION: (iii) NUMBER OF SEQUENCES: 5 (2) INFORMATION FOR SEQ ID NO:1: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 12 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1: TyrGlyArgArgArgArgArgGlnArgArgArgPro 1510 (2) INFORMATION FOR SEQ ID NO:2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 amino acids (B) TYPE: amino acid (D) TOPOLOGY: circular (ii) MOLECULE TYPE: peptide (ix) FEATURE: (A) NAME/KEY: Peptide (B) LOCATION: 10 (D) OTHER INFORMATION: /note="Xaa =Amino acid is amidated at C-terminal." (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2: GlyAlaAlaArgGlyAspThrProGluXaa 1510 (2) INFORMATION FOR SEQ ID NO:3: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 6 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3: GlyArgGlyAspSerPro 15 (2) INFORMATION FOR SEQ ID NO:4: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 6 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4: GlyArgGlyGluSerPro 15 (2) INFORMATION FOR SEQ ID NO:5: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 7 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5: GlyArgGlyAspSerProLys 15